‘We Created the Scene for Everyone Else’ Novo Nordisk CEO Maziar Mike Doustdar delivered a candid assessment of his company’s competitive position at the J.P. Morgan Healthcare Conference, characterizing the Danish drugmaker’s pioneering role in obesity treatment as both a
“We’re not trying to be everything for everyone. Our specialized focus has been very exciting for me.” Franco Negron, CEO of Simtra BioPharma Solutions, has transformed a 65-year sterile manufacturing legacy into an independent CDMO since the company’s carve-out from
Novo Nordisk received FDA approval Monday (22nd December) for oral Wegovy (semaglutide), marking the first oral GLP-1 receptor agonist cleared for obesity treatment. The Danish drugmaker plans a full US launch in early January 2026, with manufacturing underway at its
“Our goal is to be recognized for exceptional reliability in our services and manufacturing, while helping our customers bring the most innovative medicines to market.” Dr. Michael Quirmbach, CEO and President of CordenPharma, has overseen remarkable growth at the full-service
Novo Nordisk and Pfizer have escalated their competing bids for obesity drug developer Metsera to approximately $10 billion, transforming what began as a straightforward acquisition into a high-stakes corporate battle marked by legal challenges and regulatory scrutiny. Metsera’s board declared
“It costs about $2.5 billion to bring a drug to the market, and only about 30% of those actually succeed or meet their commercial goals when they get to the market.” Manufacturing leaders typically focus on the technical challenges directly
At Nordic Life Science Days (NLSDays), leading pharmaceutical executives from Novo Nordisk, AstraZeneca, and Roche convened to discuss the evolving landscape of cardiovascular, renal, and metabolic (CVRM) drug development. The “Transforming CVRM Health” panel revealed that despite clinical successes with
GLP-1 drugs have become a game-changer in treating obesity and type 2 diabetes, forecast to reach a $100 billion market value by 2030. However, their rapid rise raises important questions about resource allocation in pharmaceutical development and manufacturing, as well
Jon Reed, Head of Strategic Business Planning at Recipharm, recently shared insights into the CDMO’s latest innovations and market strategies. Speaking to the PharmaSource podcast at CPHI Milan, Jon explains how Recipharm, one of the largest CDMOs in the industry
What happened? Catalent, involved in producing Novo Nordisk’s top-selling GLP-1 obesity drug Wegovy, has over 50 sites globally. The acquisition follows Catalent’s strategic review due to declining revenue and issues at major manufacturing sites. The purchase price of $63.5 per
